Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum...

Area of Science:

• Oncology
• Clinical Trials
• Immunotherapy

Background:

• The phase 3 CASPIAN study evaluated first-line durvalumab plus etoposide/platinum (EP) chemotherapy in extensive-stage small-cell lung cancer (ES-SCLC).
• Durvalumab plus EP demonstrated a significant overall survival (OS) benefit compared to EP alone in treatment-naïve ES-SCLC patients.

Purpose of the Study:

• To conduct exploratory subgroup analyses of the CASPIAN study.
• To assess the efficacy and safety of durvalumab plus EP in specific patient subgroups.
• To evaluate patient-reported outcomes (PROs) based on age.

Main Methods:

• Randomized controlled trial design comparing durvalumab plus EP versus EP alone.
• Analysis of overall survival (OS) and safety across subgroups (age, sex, platinum agent).
• Assessment of patient-reported outcomes (PROs) by age group.

Main Results:

• Overall survival (OS) benefit with durvalumab plus EP was observed across subgroups including age (<70 vs ≥70), sex (male vs female), and platinum agent (cisplatin vs carboplatin).
• Rates of grade 3/4 adverse events were similar across subgroups; serious adverse events were more frequent in older patients (≥70 years).
• Immune-mediated adverse events were more common in females, and adding durvalumab did not negatively impact PROs in either age subgroup.

Conclusions:

• Durvalumab plus etoposide/platinum chemotherapy is supported as a first-line standard of care for ES-SCLC.
• Further research in elderly populations is warranted to optimize treatment strategies.